Human Reproduction, Vol. 3, No. suppl_2, pp. 35-38, 1988
© 1988 European Society of Human Reproduction and Embryology
Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT
Centre for Reproductive Medicine, Akademisch Ziekenhuis, Vrije Universiteit Brussel Laarbeeklaan, 101, B-1090, Brussels, Belgium
The combined therapy of a gonadotrophin-releasing hormone agonist (GnRH) D-Ser(TBU)6-EA10-LHRH (Buserelin) and human menopausal gonadotrophins (HMG) for ovarian stimulation for in-vitro fertilization and gamete intra-Fallopian transfer was evaluated during 84 cycles. All women selected for this therapy had previously failed stimulations with clomiphene citrate/HMG. The GnRHa prevented spontaneous luteinizing hormone surges and premature luteinization in all patients. After addition of the agonist to HMG, the cancellation rate dropped from 17 to 7% and improved the results in 72.6% of the cycles. Twenty-six per cent of the started cycles resulted in a pregnancy. Eighteen healthy children were born at term.
Key words: GnRH agonist/IVF/GIFT/luteal phase
Submitted on June 13, 1988;
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. Belva, S. Henriet, E. Van den Abbeel, M. Camus, P. Devroey, J. Van der Elst, I. Liebaers, P. Haentjens, and M. Bonduelle Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles Hum. Reprod., October 1, 2008; 23(10): 2227 - 2238. [Abstract] [Full Text] [PDF] |
||||
